Aebersold, Biolife Solutions CHRO, sells $18,285 in stock

Published 17/09/2025, 22:48
Aebersold, Biolife Solutions CHRO, sells $18,285 in stock

Sarah Aebersold, Chief Human Resources Officer at Biolife Solutions (NASDAQ:BLFS), sold 714 shares of common stock on September 15, 2025, at a price of $25.61, for a total value of $18,285. According to InvestingPro data, BLFS currently trades near its 52-week high of $29.55, with analysts setting price targets between $30 and $34.

Following the transaction, Aebersold directly owns 77,357 shares of Biolife Solutions. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2024. InvestingPro analysis shows the company maintains a "GOOD" Financial Health score, with liquid assets exceeding short-term obligations by 4.4x. While currently not profitable, analysts expect positive earnings this year. Discover more insights with InvestingPro’s comprehensive research report, available along with 8 additional ProTips for BLFS.

In other recent news, BioLife Solutions reported its second-quarter 2025 financial results, highlighting a notable revenue achievement. The company recorded total revenue of $25.42 million, marking a 29% increase compared to the previous year and surpassing analyst expectations. Despite this, BioLife Solutions reported a net loss of $15.8 million, or $0.33 per share, significantly missing the projected loss of $0.03 per share due to a substantial in-process R&D expense related to the PanTHERA transaction. Following these earnings, H.C. Wainwright raised its price target for BioLife Solutions from $30 to $32, maintaining a Buy rating. Additionally, BioLife Solutions held its 2025 annual meeting where shareholders re-elected all board members and approved executive compensation. The company also ratified the appointment of Grant Thornton LLP as its independent auditor for the fiscal year ending December 31, 2025. These developments come amid investor concerns about profitability, despite the strong sales performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.